Curis (CRIS) Stock Price Up 14%

Share on StockTwits

Shares of Curis, Inc. (NASDAQ:CRIS) rose 14% during mid-day trading on Thursday . The stock traded as high as $1.51 and last traded at $1.47. Approximately 743,681 shares changed hands during trading, an increase of 219% from the average daily volume of 233,342 shares. The stock had previously closed at $1.29.

CRIS has been the subject of several recent research reports. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research lowered shares of Curis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $13.17.

The company has a market capitalization of $44.37 million, a P/E ratio of -0.82 and a beta of 1.99. The company has a debt-to-equity ratio of 38.74, a quick ratio of 2.63 and a current ratio of 2.63.

Several large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of Curis by 780.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 65,554 shares during the last quarter. Renaissance Technologies LLC grew its stake in Curis by 30.7% in the 3rd quarter. Renaissance Technologies LLC now owns 620,729 shares of the biotechnology company’s stock valued at $1,105,000 after acquiring an additional 145,809 shares during the period. Fosun International Ltd acquired a new stake in Curis in the 4th quarter valued at $149,000. Bank of New York Mellon Corp boosted its stake in Curis by 196.7% during the 4th quarter. Bank of New York Mellon Corp now owns 66,588 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 44,147 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Curis by 21.5% during the 4th quarter. Geode Capital Management LLC now owns 218,803 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 38,789 shares during the last quarter. Institutional investors and hedge funds own 23.11% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://weekherald.com/2019/03/14/curis-cris-stock-price-up-14.html.

About Curis (NASDAQ:CRIS)

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Read More: What is a Candlestick Chart?

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply